Please find below a full list of references used in the Cough into Context report.

References
  1. World Health Organisation. Chronic Obstructive Pulmonary Disease (COPD). Fact Sheet No. 315. 2006
  2. Healthcare Commission. Clearing the Air: A national study of chronic obstructive pulmonary disease.© 2006 Commission for Healthcare Audit and Inspection. Available from: www.healthcarecommission.org.uk
  3. British Lung Foundation. Lost in Translation: bridging the communication gap in COPD. 2006. Available from: www.lunguk.org
  4. Stang P, Lydick E, Silberman C, Kempel A, Keating ET. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest. 2000; 117: 354-359
  5. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2006
  6. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. Clinical Guideline 12. February 2004. Available from: www.nice.org.uk
  7. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57: 847-852
  8. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jefferies DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive disease. American Journal of Respiratory and Critical Care Medicine. 1998; 157:1418-1422
  9. Roberts CM, Barnes S, Lowe D, Pearson MG. Evidence for a link between mortality in acute COPD and hospital type and resources. Thorax. 2003; 58: 947-949
  10. Graham JJ, Timmis A, Cooper J, Ramdany S, Deaner A, Ranjadayalan K, Knight C. Impact of the National Service Framework for coronary heart disease on treatment and outcome of patients with acute coronary syndromes. Heart. 2006; 92: 301-306
  11. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2001; 164: 358-364
  12. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. European Respiratory Journal.1995; 8: 1333-1338
  13. Balter SM, La Forge J, Low DE, Mandell L, Grossman RF, Chronic Bronchitis Working Group. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Canadian Respiratory Journal. 2003; 10 (Suppl B)
  14. Association of the British Pharmaceutical Industry. Target COPD. July 2006. Available from: www.abpi.org.uk
  15. British Lung Foundation. COPD: chronic obstructive pulmonary disease. Briefing COPD. September 2006. Available from: www.lunguk.org
  16. British Thoracic Society COPD Consortium (Ipsos MORI Survey). Many smokers oblivious to 'warning signs' of killer lung disease (Press release). January 2004
  17. de Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, Janson C, Sunyer J, Jarvis D, Chinn S, Vermeire P, Svanes C, Ackermann-Liebrich U, Gislason T, Heinrich J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P. Incidence of Chronic Obstructive Pulmonary Disease in a Cohort of Young Adults According to the Presence of Chronic Cough and Phlegm. American Journal of Respiratory and Critical Care Medicine. 2007; 175: 32-39
  18. Smith JA, Calverley PMA. Cough in chronic obstructive pulmonary disease. Pulmonary pharmacology and Therapeutics. 2004; 17: 393-398
  19. Everett CF, Kastelik JA, Thompson RH, Morice AH. Chronic persistent cough in the community: a questionnaire survey. Cough. 2007; 3:5
  20. Dicpinigaitis PV, Tso R, Banauch G. Prevalence of depressive symptoms among patients with chronic cough. Chest. 2006; 130: 1839-1843
  21. Donaldson GC, Wedzicha JA. COPD Exacerbations - 1: Epidemiology (Review). Thorax. 2006; 61: 164-168
  22. Guidelines in Action: A Step-by-Step Plan to Implement NICE Guidance in Your Practice. Pulse(Suppl.). June 2006
  23. Anthonisen NR, Manfreda J, Warren CP. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine. 1987; 106(2): 196-204
  24. General Practice Airways Group. Diagnosis and management of chronic obstructive pulmonary disease in primary care: A guide for those working in primary care. Publication Ref 1001. 2005: Edition 1. Available from: http://www.gpiag.org
  25. Mohanty KC, Thiappanna G, Singh V, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. Journal of Clinical Research. 2001; 4: 35-39
  26. Morice AH, McGarvey L, Pavord I. BTS Guidelines: Recommendations for the management of cough in adults. Thorax. 2006; 61 (Suppl. 1): i1-i24
  27. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. European Respiratory Journal. 2003; 22: 672–688
  28. Galen, data on file
  29. Price LC, Lowe D, Hosker HSR, Anstey K, Pearson MG, Roberts CM. UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax. 2006: 61; 837-842
  30. British Thoratic Society. Audit shows care of patients with COPD not good enough. 9th February 2005. Available from: www.brit-thoracic.org.uk
  31. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60: 925-931
  32. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal. 2004; 23: 698–702
  33. Connors AF Jnr, Dawson NV, Thomas C, Harrell FE Jnr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. American Journal of Respiratory and Critical Care Medicine. 1996; 154: 959-967
  34. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004; 59(1): 1-232
  35. Begany T. Sputum color is the key to treating acute COPD exacerbations. PulmonaryReviews.com. 2000; 5(8) [Online]
  36. Wedzicha JA. Airway infection accelerates decline of lung function in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2001; 164: 1757-1760
  37. Soler N, Agustí C, Angrill J, Puig De la Bellacasa J, Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax. 2007; 62: 29-35
  38. Barnes PJ. Future treatments. British Medical Journal. 2006; 333: 246-248
  39. Dal Negro RW, Visconti M, Micheletto C, Tognella S. Antioxidant effects of erdosteine in current smokers with mild COPD (Gold Class 0-2). Poster presented at European Respiratory Society Annual Congress. 2-6 Sept 2006, Munich, Germany
  40. Bowler RP, Barnes PJ, Crapo JD. The role of oxidative stress in chronic obstructive pulmonary disease. COPD. 2004; 1(2): 255-77
  41. Dekhuijzen PNR, Aben KKH, Dekker I, Aarts LPHJ, Wielders PLML, van Herwaarden CLA, Bast A. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine. 1996; 154(1)3: 813-816
  42. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax. 2003; 58: 294-298
  43. Drost EM , Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD Thorax. 2005; 60: 293-300
  44. Anthonisen RN, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O’Hara P,Owens GR, Scanlon PD, Tashkin DP, Wise RA. Effects of smoking intervenetion and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. Journal of the American Medical Association. 1994; 272(19): 1497-1505
  45. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The Effects of a Smoking Cessation Intervention on 14.5- Year Mortality. Annals of Internal Medicine. 2005; 142: 233-239
  46. Wynder EL, Kaufman PL, Lesser RL. A short-term follow-up study on ex-cigarette smokers: with special emphasis on persistent cough and weight gain. American Review of Respiratory Disease. 1967; 96(4): 645-55
  47. Sitkauskiene B, Stravinskaite K, Sakalauskas R, Dicpinigaitis PV. Changes in cough reflex sensitivity after cessation and resumption of cigarette smoking. Pulmonary Pharmacology & Therapeutics. 2007; 20(3): 240-243
  48. Dicpinigaitis PV, Sitkauskiene B, Stravinskaite K, Appel DW, Negassa A, Sakalauskas R. Effect of smoking cessation on cough reflex sensitivity. European Respiratory Journal. 2006; 28(4): 786-90
  49. Van Schayck CP, Loozen JMC, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. British Medical Journal. 2002; 324: 1370
  50. General Practice Airways Group. GPIAG Opinion No.2: Mucolytics. 2004. Available from: www.gpiag.org
  51. American Thoracic Society & European Respiratory Society. Standards for the diagnosis and management of paitents withCOPD. 2004. Available from: dev.ersnet.org
  52. Rennard SI. Treatment of stable chronic obstructive pulmonary disease. Lancet. 2004; 364(9436): 791-802
  53. Busin S, Clerici R, Nitti F. Erdosteine: evaluation of mucorheological and mmunosecretory parameters in patients with bronchial phlogistic pathology. Med Praxis. 1991; 12(4): 197-205
  54. Marchioni CF, Polu JM, Taytard A, Hanard T, Noseda G, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). International Journal of Clinical Pharmacology and Therapeutics. 1995; 33(11): 612-618
  55. Bisetti A, Mancini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo. Archivio di Medicina Interna.1995; XLVII(4): 89-97
  56. Tellings JC. Erdotsteine: original secretolytic drug with mucociliar activity: a controlled clinical study versus Ambroxol. Med Praxis. 1991; 12(4): 183-195
  57. Braga PC, Dal Sasso M, Sala MT, Gianelle V. Effects of erdotsteine and its metabolites on bacterial adhesiveness. Arzneim Forsch/Drug Research. 1999; 49(I)4: 344-350
  58. Mitrea M, Silvestro L, Savu S, Mancini C. Reduced (GSH) and oxidized (GSSG) levels in plasma and BAL of chronic bronchitis patients treated with erdosteine or N-acetylcysteine (NAC). Abstract presented at 6th International Conference on Bronchoalveolar Lavage, 24-27 June 1998, Corfu, Greece
  59. Mancini C, Silvestro G, Savu S. Pilot study on erdosteine activity on reduced glutathione (GSH) plasmatic levels in correlation with levels of the mother compound and main metabolite (Nthiodiglycolylhomocysteine. Abstract presented at 4th European Congress of Pharmaceutical Sciences, 11-13 Sept 1998, Milan, Italy